Please login to the form below
MyoKardia
This page shows the latest MyoKardia news and features for those working in and with pharma, biotech and healthcare.
BMS builds case for cardiovascular drug mavacamten with new analysis
BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year. ... BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia, announced last year.
Latest news
-
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
BMS gained the rights to mavacamten as part of its acquisition of MyoKardia. ... BMS picked up mavacamten as part of its $13.1bn acquisition of MyoKardia, announced last year.
-
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
As part of the merger, BMS has now gained the rights to MyoKardia’s investigational treatment mavacamten, which is currently in development for obstructive hypertrophic cardiomyopathy (HCM). ... The addition of MyoKardia’s pipeline cardiovascular
-
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
Earlier this week, Bristol Myers Squibb (BMS) announced that it was set to acquire cardiovascular specialist MyoKardia for $13.1bn. ... In the process, BMS will gain the rights to MyoKardia’s investigational treatment mavacamten, which is currently
-
Sanofi bets on DiCE to find oral alternatives to injectable drugs
Other partnerships in Sanofi's Sunrise initiative include a $200m cardiomyopathy project with MyoKardia, and funding agreements with start-ups Warp Drive Bio - focusing on the use of genomics to discover
-
Sanofi licenses cardiomyopathy programme in $200m deal
MyoKardia's approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. ... The deal with MyoKardia has been set up under Sanofi's Sunrise initiative, which focuses on
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
MyoKardia is gathering PROs in its phase 2 hypertrophic cardiomyopathy trial.
-
Pharma deals during September 2014
It certainly would have been simpler, but probably more expensive, if Sanofi had acquired MyoKardia! ... That may still be on the cards as Sanofi has made an equity investment in MyoKardia as part of the upfront.
-
Deal Watch table for September 2014
209. MyoKardia/ Sanofi. Licence and collaboration. 5. Three programmes for treatment of genetic forms of cardiomyopathy.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
MyoKardia appoints COO and medical affairs VP
California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice president of medical affairs. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a
-
Jonathan Fox leaves AstraZeneca for MyoKardia
Will lead programme to target genetic heart disease. MyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer. ... Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
